NASDAQ:ONCY - Oncolytics Biotech News Headlines

$0.63
+0.09 (+16.67 %)
(As of 08/18/2019 04:00 PM ET)
Today's Range
$0.55
Now: $0.63
$0.74
50-Day Range
$0.57
MA: $1.40
$1.74
52-Week Range
$0.53
Now: $0.63
$5.12
Volume1.26 million shs
Average Volume293,125 shs
Market Capitalization$12.83 million
P/E RatioN/A
Dividend YieldN/A
Beta2.05

Headlines

Oncolytics Biotech (NASDAQ ONCY) News Headlines

Source:
DateHeadline
The Daily Biotech Pulse: Regenerons Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics OfferingThe Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering
www.benzinga.com - August 14 at 4:02 PM
CORRECTION: Oncolytics Biotech(R) Announces Pricing of Its USD $3.7M - CDN $4.9M Public Offering of Common Share and WarrantsCORRECTION: Oncolytics Biotech(R) Announces Pricing of Its USD $3.7M - CDN $4.9M Public Offering of Common Share and Warrants
finance.yahoo.com - August 14 at 4:02 PM
Oncolytics Biotech(R) Announces First Patient Treated in Companys AWARE-1 Window of Opportunity Study of Pelareorep in Breast CancerOncolytics Biotech(R) Announces First Patient Treated in Company's AWARE-1 Window of Opportunity Study of Pelareorep in Breast Cancer
finance.yahoo.com - April 8 at 8:53 AM
Oncolytics Biotech(R) to Present at the 18th Annual Needham Healthcare ConferenceOncolytics Biotech(R) to Present at the 18th Annual Needham Healthcare Conference
finance.yahoo.com - April 3 at 8:51 AM
Oncolytics Biotech (R) Presents Positive Clinical Biomarker Data at the American Association for Cancer Research Annual Meeting 2019Oncolytics Biotech (R) Presents Positive Clinical Biomarker Data at the American Association for Cancer Research Annual Meeting 2019
finance.yahoo.com - April 2 at 4:23 PM
Oncolytics Biotech Inc. Estimate MomentumOncolytics Biotech Inc. Estimate Momentum
www.nasdaq.com - March 18 at 4:06 PM
Oncolytics Biotech Inc. (ONCY) CEO Matthew Coffey on Q4 2018 Results - Earnings Call TranscriptOncolytics Biotech Inc. (ONCY) CEO Matthew Coffey on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 8 at 12:25 PM
Oncolytics Biotech(R) Announces Spanish Regulatory Approval of AWARE-1 Window of Opportunity Study in Breast CancerOncolytics Biotech(R) Announces Spanish Regulatory Approval of AWARE-1 Window of Opportunity Study in Breast Cancer
finance.yahoo.com - February 11 at 8:43 AM
Oncolytics Biotech(R) to Present at the 21st Annual BIO CEO & Investor ConferenceOncolytics Biotech(R) to Present at the 21st Annual BIO CEO & Investor Conference
finance.yahoo.com - February 4 at 8:51 AM
Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib andOncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and
www.nasdaq.com - December 12 at 11:05 AM
Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple MyelomaOncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma
finance.yahoo.com - December 12 at 11:05 AM
Oncolytics Biotech (ONCY) Announces First Patient Treated in Phase 2 Study Combining Pelareorep and KeytrudaOncolytics Biotech (ONCY) Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda
www.streetinsider.com - November 26 at 9:56 AM
Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancreatic CancerOncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancreatic Cancer
finance.yahoo.com - November 26 at 9:56 AM
Oncolytics Biotech® Announces Attendance of Upcoming ConferencesOncolytics Biotech® Announces Attendance of Upcoming Conferences
finance.yahoo.com - November 13 at 9:13 AM
Oncolytics Biotech Inc. (ONCY) CEO Matt Coffey on Q3 2018 Results - Earnings Call TranscriptOncolytics Biotech Inc. (ONCY) CEO Matt Coffey on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 12 at 3:23 PM
Oncolytics Biotech® Announces Presentation at the Society for Immunotherapy of Cancer 2018 Annual Meeting Showcasing Upregulation of PD-L1 Expression with Reovirus InfectionOncolytics Biotech® Announces Presentation at the Society for Immunotherapy of Cancer 2018 Annual Meeting Showcasing Upregulation of PD-L1 Expression with Reovirus Infection
finance.yahoo.com - November 9 at 9:30 AM
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Corporate HighlightsOncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Corporate Highlights
finance.yahoo.com - November 5 at 8:46 AM
Oncolytics Biotech® Establishes New At-The-Market FacilityOncolytics Biotech® Establishes New At-The-Market Facility
finance.yahoo.com - October 25 at 8:45 AM
Tiziana Life IPO: Phase 2 Of Development, But Expensive SharesTiziana Life IPO: Phase 2 Of Development, But Expensive Shares
seekingalpha.com - October 23 at 3:22 PM
Oncolytics Biotech® Announces Positive Clinical Trial Results for Pelareorep in Patients with KRAS Mutant Metastatic Colorectal Cancer for Presentation at ESMO 2018Oncolytics Biotech® Announces Positive Clinical Trial Results for Pelareorep in Patients with KRAS Mutant Metastatic Colorectal Cancer for Presentation at ESMO 2018
finance.yahoo.com - October 22 at 8:36 AM
Oncolytics Biotech (ONCY) Reports Publication of Positive Clinical Results for Pelareorep at ESMO 2018 CongressOncolytics Biotech (ONCY) Reports Publication of Positive Clinical Results for Pelareorep at ESMO 2018 Congress
www.streetinsider.com - October 11 at 8:21 AM
Oncolytics Biotech® Announces Publication of Positive Clinical Results for Pelareorep in Abstract for ESMO 2018 CongressOncolytics Biotech® Announces Publication of Positive Clinical Results for Pelareorep in Abstract for ESMO 2018 Congress
finance.yahoo.com - October 11 at 8:21 AM
Oncolytics (ONCY) Says Publication Shows Pelareorep Effectively Targets Tumors Even in Presence of Neutralizing AntibodiesOncolytics (ONCY) Says Publication Shows Pelareorep Effectively Targets Tumors Even in Presence of Neutralizing Antibodies
www.streetinsider.com - October 3 at 8:18 AM
Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors Even in the Presence of Neutralizing AntibodiesOncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors Even in the Presence of Neutralizing Antibodies
finance.yahoo.com - October 2 at 8:24 AM
Oncolytics Biotech (ONCY) Announces Common Stock Purchase Agreement for up to $26 Million with Lincoln Park CapitalOncolytics Biotech (ONCY) Announces Common Stock Purchase Agreement for up to $26 Million with Lincoln Park Capital
www.streetinsider.com - September 28 at 3:21 PM
Oncolytics Biotech® to Present at the Ladenburg Thalmann 2018 Healthcare ConferenceOncolytics Biotech® to Present at the Ladenburg Thalmann 2018 Healthcare Conference
finance.yahoo.com - September 26 at 8:17 AM
Oncolytics Bio to update investors on business tomorrow morningOncolytics Bio to update investors on business tomorrow morning
seekingalpha.com - September 20 at 7:46 AM
Oncolytics Biotech (ONCY) Provides Corporate, Clinical UpdateOncolytics Biotech (ONCY) Provides Corporate, Clinical Update
www.streetinsider.com - September 20 at 7:46 AM
Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) with Standard of CareOncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) with Standard of Care
finance.yahoo.com - September 17 at 7:48 AM
Oncolytics Biotech collaborates with SOLTI to conduct a window of opportunity study in breast cancer with pelareorepOncolytics Biotech collaborates with SOLTI to conduct a window of opportunity study in breast cancer with pelareorep
seekingalpha.com - September 10 at 3:19 PM
Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with PelareorepOncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep
finance.yahoo.com - September 10 at 7:41 AM
Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical ProgramOncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical Program
finance.yahoo.com - September 6 at 7:43 AM
Oncolytics Biotech® Reports 2018 Second Quarter ResultsOncolytics Biotech® Reports 2018 Second Quarter Results
finance.yahoo.com - August 3 at 3:17 PM
Oncolytics: Significant Pipeline Value In The Fastest Growing Area Of Oncology.Oncolytics: Significant Pipeline Value In The Fastest Growing Area Of Oncology.
seekingalpha.com - July 11 at 3:16 PM
Media Advisory - Oncolytics Biotech® Inc. Announces Participation In Upcoming ConferencesMedia Advisory - Oncolytics Biotech® Inc. Announces Participation In Upcoming Conferences
www.thestreet.com - February 9 at 12:04 PM
Oncolytics Biotech (ONCY) Commences Dosing in KEYTRUDA + REOLYSIN Phase 1b - StreetInsider.comOncolytics Biotech (ONCY) Commences Dosing in KEYTRUDA + REOLYSIN Phase 1b - StreetInsider.com
www.streetinsider.com - January 20 at 5:51 PM
Oncolytics Biotech® Inc. Announces First Patients Treated in Phase 1b Study in Advanced Pancreatic Cancer - PR Newswire (press release)Oncolytics Biotech® Inc. Announces First Patients Treated in Phase 1b Study in Advanced Pancreatic Cancer - PR Newswire (press release)
www.prnewswire.com - January 20 at 5:51 PM
This page was last updated on 8/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel